Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

The FDA has approved obinutuzumab (Gazyva) as the first drug specifically for adults with primary membranous nephropathy. In the phase 3 MAJESTY trial, 36% of patients on obinutuzumab achieved complete proteinuria remission vs. just 6% on tacrolimus. This marks a major milestone for a condition that previously had no approved adult therapy.
The FDA has approved obinutuzumab (Gazyva, Genentech) for proteinuria remission in adults with primary membranous nephropathy (PMN) who are at risk for disease progression — making it the first drug ever approved for this indication in adults. The humanized monoclonal antibody targets CD20 on B cells and had previously been approved for pediatric idiopathic nephrotic syndrome and adult lupus nephritis.
The approval was based on results from the phase 3 MAJESTY trial, published in The New England Journal of Medicine, which randomized 142 adults with PMN to either obinutuzumab or tacrolimus.
By the Numbers:
Why it matters: Primary membranous nephropathy is a leading cause of nephrotic syndrome in adults, and until now, no FDA-approved treatment existed for this population. Obinutuzumab's approval fills a critical gap, offering clinicians a validated, targeted option backed by robust phase 3 data.